Cytodyn Inc (CYDY)

$0.32 0.00 (-1.38%)
Market Cap 408.49M
Revenue (ttm) 0.00
Net Income (ttm) 3.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 851,700
Avg Vol 1,833,626
Day's Range N/A - N/A
Shares Out 1.27B
Stochastic %K 52%
Beta 1.33
Analysts Strong Buy
Price Target $4.00

Company Profile

CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. The co...

Industry: Biotechnology
Sector: Healthcare
Phone: 360 980 8524
Fax: 360 799 5954
Address:
1111 Main Street, Suite 660, Vancouver, United States
u2rocksme
u2rocksme Dec. 14 at 12:20 PM
$CYDY BULLISH!!! HAVE A GREAT WEEKEND LONGS!!!
0 · Reply
Tomleon
Tomleon Dec. 14 at 11:59 AM
$CYDY 7126👀 good morning Longs!
0 · Reply
CYDY7247
CYDY7247 Dec. 14 at 9:46 AM
$CYDY No matter how hard they tried to derail Cytodyn; it never died. Now it’s too late! Indestructible….like the Horsemen whom protect this kingdom whilst you sleep. Sleep sheep sleep…
0 · Reply
Twinter11
Twinter11 Dec. 14 at 5:38 AM
$CYDY
1 · Reply
Twinter11
Twinter11 Dec. 14 at 5:33 AM
$CYDY no wonder they tryin kill us off Can't have one drug fixing everything They had their chance Too late now.
0 · Reply
Twinter11
Twinter11 Dec. 14 at 5:24 AM
$CYDY Breast phyllodes tumors recruit and repolarize tumor-associated macrophages via secreting CCL5 to promote malignant progression which can be inhibited by CCR5 inhibition Therapy "Results: High level of malignant PT-secreted CCL5 correlated with the poor outcome of PTs and could be an independent prognostic factor of PTs. CCL5 bound to its receptor CCR5 on macrophages, thus activated AKT signaling to recruit and repolarize TAMs. Subsequently, the TAMs released CCL18 to further promote the aggressive phenotype of malignant PTs by enhancing and maintaining the myofibroblast differentiation and invasion in vitro and in vivo. In murine PDX model of human malignant PTs, CCL5-CCR5 axis blocked by (maraviroc), an FDA proved CCR5 inhibitor, prevented monocytes recruitment to the tumor and dramatically suppressed the tumor growth"... https://share.google/xqN9NsoI3xrDnCuBg
1 · Reply
Twinter11
Twinter11 Dec. 14 at 5:09 AM
$CYDY Identifying how the brain links memories – and how an HIV drug can combat memory loss "Alcino Silva, a distinguished neurobiology and psychiatry professor at the Geffen School of Medicine, has found that as people age, the amount of CCR5 gene expressed in the brain increases, reducing memory recall. To counteract memory loss, the team explored the effects of ((replace w/ leron))(maraviroc), a drug that targets CCR5 to slow HIV progression in patients. When researchers gave maraviroc to older mice, the drug suppressed the gene and the mice were able to resume linking memories". Best Bruin research and innovations that powered progress | UCLA https://share.google/KrDZxehxqXcwqpMit
0 · Reply
Twinter11
Twinter11 Dec. 14 at 5:03 AM
$CYDY Adverse Events to CAR T for Multiple Myeloma Linked to CCR5 Pathway ..."Researchers at the University of Pennsylvania have discovered that delayed side effects such as neurotoxicity and intestinal inflammation that can appear weeks or months after B-cell maturation antigen–directed (BCMA) CAR T cell therapy for multiple myeloma have a common root cause and correlate to high rates of death unrelated to cancer relapse, primarily infections"... ..."These results suggest a potential IL-15–driven CCL5–CCR5 loop sustaining CART expansion,”... ..."However, the identification of the IL-15–CCL5–CCR5 circuit suggests a potential non-steroid approach. The researchers noted that CCR5 blockade “safely restrains CART-BCMA expansion while preserving their anti-myeloma activity.” https://share.google/gjclZLUJn4ToZo4bd
0 · Reply
CYDY7333
CYDY7333 Dec. 14 at 3:17 AM
$CYDY Beware of the enemy coming hard after us down the stretch of December’s brutal cold. get it @Cytomight coming hard and down the stretch 😉
0 · Reply
Sheen_CYDY
Sheen_CYDY Dec. 14 at 12:43 AM
$CYDY 7200 soon
2 · Reply
Latest News on CYDY
No data available.
u2rocksme
u2rocksme Dec. 14 at 12:20 PM
$CYDY BULLISH!!! HAVE A GREAT WEEKEND LONGS!!!
0 · Reply
Tomleon
Tomleon Dec. 14 at 11:59 AM
$CYDY 7126👀 good morning Longs!
0 · Reply
CYDY7247
CYDY7247 Dec. 14 at 9:46 AM
$CYDY No matter how hard they tried to derail Cytodyn; it never died. Now it’s too late! Indestructible….like the Horsemen whom protect this kingdom whilst you sleep. Sleep sheep sleep…
0 · Reply
Twinter11
Twinter11 Dec. 14 at 5:38 AM
$CYDY
1 · Reply
Twinter11
Twinter11 Dec. 14 at 5:33 AM
$CYDY no wonder they tryin kill us off Can't have one drug fixing everything They had their chance Too late now.
0 · Reply
Twinter11
Twinter11 Dec. 14 at 5:24 AM
$CYDY Breast phyllodes tumors recruit and repolarize tumor-associated macrophages via secreting CCL5 to promote malignant progression which can be inhibited by CCR5 inhibition Therapy "Results: High level of malignant PT-secreted CCL5 correlated with the poor outcome of PTs and could be an independent prognostic factor of PTs. CCL5 bound to its receptor CCR5 on macrophages, thus activated AKT signaling to recruit and repolarize TAMs. Subsequently, the TAMs released CCL18 to further promote the aggressive phenotype of malignant PTs by enhancing and maintaining the myofibroblast differentiation and invasion in vitro and in vivo. In murine PDX model of human malignant PTs, CCL5-CCR5 axis blocked by (maraviroc), an FDA proved CCR5 inhibitor, prevented monocytes recruitment to the tumor and dramatically suppressed the tumor growth"... https://share.google/xqN9NsoI3xrDnCuBg
1 · Reply
Twinter11
Twinter11 Dec. 14 at 5:09 AM
$CYDY Identifying how the brain links memories – and how an HIV drug can combat memory loss "Alcino Silva, a distinguished neurobiology and psychiatry professor at the Geffen School of Medicine, has found that as people age, the amount of CCR5 gene expressed in the brain increases, reducing memory recall. To counteract memory loss, the team explored the effects of ((replace w/ leron))(maraviroc), a drug that targets CCR5 to slow HIV progression in patients. When researchers gave maraviroc to older mice, the drug suppressed the gene and the mice were able to resume linking memories". Best Bruin research and innovations that powered progress | UCLA https://share.google/KrDZxehxqXcwqpMit
0 · Reply
Twinter11
Twinter11 Dec. 14 at 5:03 AM
$CYDY Adverse Events to CAR T for Multiple Myeloma Linked to CCR5 Pathway ..."Researchers at the University of Pennsylvania have discovered that delayed side effects such as neurotoxicity and intestinal inflammation that can appear weeks or months after B-cell maturation antigen–directed (BCMA) CAR T cell therapy for multiple myeloma have a common root cause and correlate to high rates of death unrelated to cancer relapse, primarily infections"... ..."These results suggest a potential IL-15–driven CCL5–CCR5 loop sustaining CART expansion,”... ..."However, the identification of the IL-15–CCL5–CCR5 circuit suggests a potential non-steroid approach. The researchers noted that CCR5 blockade “safely restrains CART-BCMA expansion while preserving their anti-myeloma activity.” https://share.google/gjclZLUJn4ToZo4bd
0 · Reply
CYDY7333
CYDY7333 Dec. 14 at 3:17 AM
$CYDY Beware of the enemy coming hard after us down the stretch of December’s brutal cold. get it @Cytomight coming hard and down the stretch 😉
0 · Reply
Sheen_CYDY
Sheen_CYDY Dec. 14 at 12:43 AM
$CYDY 7200 soon
2 · Reply
Twinter11
Twinter11 Dec. 14 at 12:38 AM
$CYDY 11 months ago we were screwed. 9 months ago we were going to win no matter what I dont know when or how but it's gonna happen. There is no way anyone getting in now is gonna lose Thats what I think.
1 · Reply
Cytomight
Cytomight Dec. 13 at 9:51 PM
$CYDY very very, very, very significant‼️ https://www.reddit.com/r/Livimmune/s/L1MNrLzWWo
4 · Reply
WheelsAreRolling
WheelsAreRolling Dec. 13 at 9:47 PM
$CYDY I usually fire people like Mazzy
2 · Reply
Twinter11
Twinter11 Dec. 13 at 8:44 PM
$CYDY maz= https://www.reddit.com/user/BGFGiraffe/
1 · Reply
SpiderPlant40
SpiderPlant40 Dec. 13 at 8:16 PM
$CYDY I forgot to mention Statistically Significant p-value of 0.0418 longer survival with higher dose Leronlimab. Dr J has the answers before we even ask the ?s From the poster: Compared to patients treated with the 350 mg QW SC dose of leronlimab, patients treated with either the 525 or 700 mg QW SC dose of leronlimab demonstrated significantly longer survival (HR 3.44, 95% CI: 1.2–9.9; P=0.0418) (Fig. 2). Stat Sig is so much better than 6-7 Maybe Stat Sig will be 2026 Word of the Year 😁
2 · Reply
Twinter11
Twinter11 Dec. 13 at 8:06 PM
$CYDY Nobody cares but me. BGFGiraffe over on the pennystocks reddit ( and a couple cydy subreddit threads ) thread is maz I busted it a while back and scrolled through its old reddit posts about fantasy football and whatever. I went back just now to do a deep dive but all its old posts had been removed since I busted it and let it know. It probably knew there was more personally identifiable info so it did house keeping. so i shoulda went deeper back when i first found it. Cant fool Inspector Detector.
5 · Reply
SpiderPlant40
SpiderPlant40 Dec. 13 at 8:03 PM
$CYDY How many of the 10 patients that moved from 350mg to 525mg were already too far gone & too late to respond to treatment? These trials included patients w median of 2 prior metastic therapies so the trial was a last ditch effort for patients already too close to death Notice the chart 6/7 patients on the right w 'No follow-up CTC samples available' were marked LD=Low Dose Leronlimab 325mg dose. Most didn't make it so no chance for measuring PD-L1 on CTCs ICIs take 2-4 months to start showing measurable results as it's a gradual process training immune system so early LRM treatment=survival LRM should be 1st line treatment Patients weight & size impacts dosage in treatments & Leronlimab is similar. Safe to say more CCR5 receptors in a larger patient so dosage should be higher...patient specific. SubQ does max=700mg, maybe dose every 5 days instead of 7 w taller/heavier patients DR J mentioned dose escalation Cancer & HIV may require different dose timelines 700mg dose data is the key
1 · Reply
Nyasaland
Nyasaland Dec. 13 at 7:31 PM
$CYDY sad for him i think he is pursuing other alternatives but shame he cant be steered towards us. https://www.espn.com/nba/story/_/id/47266076/jason-collins-stage-4-glioblastoma
1 · Reply
DASmyth
DASmyth Dec. 13 at 7:31 PM
$CYDY No love from AI yet. Yet.
0 · Reply
WheelsAreRolling
WheelsAreRolling Dec. 13 at 7:22 PM
$CYDY
0 · Reply
WheelsAreRolling
WheelsAreRolling Dec. 13 at 7:21 PM
$CYDY
0 · Reply
mazzystar1
mazzystar1 Dec. 13 at 6:46 PM
$CYDY apologies for the delay... have a great weekend!!!
3 · Reply